Company news

Keymed Biosciences, Inc. news in 2023

Keymed Biosciences, Inc.'s news releases, calls and decks from 2023, newest first.

View company

License agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate, completed

March 30, 2023

Keymed Biosciences Announces 2022 Annual Results: Efficiently Promotes Clinical Progress & Proactively Develops Global Strategic Collaboration

March 16, 2023